Investing.com - Plus Therapeutics (NASDAQ: PSTV) reported fourth quarter EPS of $-0.770, $0.62 worse than the analyst estimate of $-0.150. Revenue for the quarter came in at $220K versus the consensus estimate of $1.48M.
Plus Therapeutics's stock price closed at $0.390. It is down -9.700% in the last 3 months and down -61.190% in the last 12 months.
Plus Therapeutics saw 3 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Plus Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Plus Therapeutics's Financial Health score is "weak performance".
Check out Plus Therapeutics's recent earnings performance, and Plus Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar